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The Association of A Number of Predictive Factors for The Recurrence of Papillary Urothelial Neoplasm 
of Low Malignant Potential: Prognostic Analysis From Multiple Academic Centers
Ki Hong Kim1, Seung Hwan Lee2, Sun Il Kim3, Byung Ha Chung4, Kyo Chul Koo4, Jin Seon Cho5, Woo Jin Bang5, 
Jong Yeon Park6, Sung Joon Hong2*
Purpose: To identify clinically useful predictors for the recurrence of papillary urothelial neoplasm of low ma-
lignant potential (PUNLMP), we reviewed the clinical information of patients who were diagnosed and treated in 
multiple tertiary-care academic facilities. 
Materials and Methods: Between February 2007 and April 2015, 95 patients diagnosed with PUNLMP after tran-
surethral resection of bladder (TURB) were included in this study. Age, gender, body mass index, smoking history, 
the presence or absence of previous history of urothelial neoplasm, the presence or absence of gross hematuria, 
cytological results at the time of diagnosis, tumor diameter, and multiplicity of tumor were estimated as variables 
for analysis. Cox regression tests were used for identifying predictive factors for recurrence of PUNLMP.
Results: Sixty-nine cases of PUNLMP were de novo primary bladder PUNLMPs without known urothelial lesions 
in the urinary tract, and 26 PUNLMPs were identified on surveillance biopsies of patients with a previous history 
of urothelial neoplasm. During the follow-up period, recurrences developed in 13 patients (13.7%). Recurrence 
rates were 4.2% and 9.5% at 12 and 24 months, respectively. On univariate and multivariate Cox regression analy-
ses, previous history of urothelial neoplasm [95% confidence interval (CI): 0.057-0.604, hazard ratio (HR) = 0.185, 
P = .005] and multiplicity of tumors [95% CI = 0.064-0.584, HR = 0.193, P = .004] were identified as independent 
predictors for recurrence-free survival of patients with PUNLMP.
Conclusion: Tumor multiplicity and previous history of urothelial neoplasm are independent prognostic factors for 
prediction of recurrence of PUNLMP. More careful and closer follow-up should be recommended for PULNMP 
patients with tumor multiplicity or a previous history of urothelial neoplasm.
Keywords: papillary urothelial neoplasm of low malignant potential; recurrence rate; prognosis; prediction factor
INTRODUCTION
The term ‘papillary urothelial neoplasm of low ma-lignant potential’ (PUNLMP) was introduced at the 1998 World Health Organization/International Society 
of Urological Pathology (WHO/ISUP) meeting(1) In 
2004, WHO/ISUP separated the noninvasive papillary 
neoplasms into four categories: urothelial papilloma, 
PUNLMP, low-grade urothelial carcinoma, and high-
grade urothelial carcinoma.(2) These four categories 
replaced the 1973 WHO classification in which urothe-
lial papilloma was categorized according to carcinoma 
grades 1 to 3,(1,3) and this system has been widely used 
in the clinical or pathologic fields.(4-6)  Histologically, 
PUNLMP was defined as a ‘papillary urothelial lesion 
with an orderly arrangement of cells within papillae 
with minimal architectural abnormalities and minimal 
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nuclear atypia irrespective of cell thickness.(1) 
Several studies about PUNLMP demonstrate that the 
risk rate of recurrence ranges from 17.9% to 60%, and 
the histological progression rate is 1.9% to 29.0%.(4-
8) Clinical predictors for recurrence of PUNLMP have 
been shown to include age, tumor size, and tumor mul-
tiplicity.(4,6,7,9) Histopathologic predictors include mi-
toses, chromatin organization state, global acetylation, 
methylation changes, and subtle architectural disorder.
(4,10-14) 
The histopathologic predictive factors that have been 
identified to date have the limitation that they cannot 
be applied easily in the clinical field. Additionally, 
previous studies about clinical predictors of PUNLMP 
have the limitation that they were relatively small-scale 
studies that were performed in single center. These 
limitations indicate that further efforts for identifying 
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prognostic factors of PUNLMP are needed. The current 
study was therefore conducted to investigate clinically 
useful predictors for the recurrence of PUNLMP in pa-
tients who were diagnosed and treated in multiple ter-
tiary-care academic facilities.
PATIENTS AND METHODS
Patients 
Five Korean institutions (Shinchon Severance Hospital, 
Yonsei University College of Medicine; Ajou Univer-
sity School of Medicine; Gangnam Severance Hospital, 
Yonsei University College of Medicine; Hallym Uni-
versity College of Medicine; Gangneung Asan Hospi-
tal, University of Ulsan College of Medicine) contribut-
ed data to this study. Between February 2007 and April 
2015, 95 patients who were diagnosed with PUNLMP 
after transurethral resection of bladder (TURB) were 
included in this study. The patients were assessed by 
urine cytology and cystoscopy every 3 months for 2 
years after TURB, every 6 months for the next 3 years, 
and yearly thereafter. The patients also had a computed 
tomography scan yearly. Recurrence was defined as the 
histopathologically proven reappearance of any urothe-
lial neoplasm during the follow-up period, and progres-
sion was defined as recurrence to a higher-grade neo-
plasm. Histopathologic diagnosis was classified using 
the 2004 WHO/ISUP criteria.(1,15) The medical ethics 
committee of Severance Hospital,
Yonsei University Health Care System (Seoul, Korea) 
approved this retrospective study. After receiving insti-
tutional review board approval, we conducted a retro-
spective chart review of included patients. 
Clinical data and statistical analysis
Age, gender, body mass index, smoking history, the 
presence or absence of previous history of urothelial 
neoplasm, the presence or absence of gross hematuria, 
cytological results at the time of diagnosis, tumor di-
ameter, and multiplicity of tumor were estimated as 
variables for analysis. Gross hematuria was defined as 
the case in which the hematuria was visually confirmed, 
and tumor multiplicity was defined as the presence of 
tumors at 2 or more sites in the cystoscopy.
The end point of the study was recurrence-free survival 
(RFS), and RFS defined as the time interval between 
inital TURB and first recurrence. Statistical analyses to 
identify independent predictors for RFS of PUNLMP 
were performed using univariate and multivariate Cox’s 
proportional hazard regression analyses. Variables that 
were significant in the univariate analysis (p<0.05) 
were entered into the multivariate model. All statistical 
analyses were performed using SPSS Statistics version 
20.0.0 (IBM Corp., Armonk, NY, USA). For all anal-
yses, a two-sided p-value of < 0.05 was considered to 
indicate statistical significance.
RESULTS
The median follow-up period after being diagnosed 
with PUNLMP after TURB was 25.3 months, and all 
included patients had tumors that were classified as 
noninvasive (Ta) PUNLMP. Baseline characteristics 
of included patients are outlined in Table 1. 69 pa-
tients had de novo primary bladder PUNLMPs without 
known urothelial lesions in the urinary tract. 26 PUN-
LMPs were diagnosed with surveillance biopsies on pa-
tients with a previous history of urothelial neoplasm. Of 
26 patients, 5 and 21 patients were classified as T1 and 
Ta, respectively. All of 26 patients were diagnosed with 
low-grade urothelial carcinoma.
During the follow-up period, recurrences developed in 
13 patients (13.7%). Recurrence rates were 4.2% and 
9.5% at 12 and 24 months, respectively. Histologic 
grade progression developed in seven patients (7.4%), 
and none of the included patients developed stage pro-
gression (> pTa). All of patients who progressed in 
histologic grade were diagnosed as having low-grade 
urothelial carcinoma. Of recurred patients, there were 
none who progressed to high-grade or either to pT1. 
Five patients died during the follow-up period from dis-
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Table 1. Patient characteristics.
Number of patients     95
Gender
 Male      74
 Female      21 
Age at being diagnosed with PUNLMP, median (years old, IQR) 63.00 ( 53.00 – 71.00)
BMI, median (kg/m2 , IQR)    24.40 (22.30 – 26.10)
Smoking history
 Presence     45
 Absence     41
 Unknown     9 
Previous history of urothelial neoplasm
 Presence     26
 Absence     69 
Gross hematuria
 Presence     56
 Absence     39 
Cytologic result
 Inadequate     1
 Negative     66
 Atypia, favor benign     10
 Atypia, favor neoplastic    7
 Suspicious malignancy    0
 Malignancy     3
 Not estimated      8
Tumor multifocality
 Presence     17
 Absence      78
Tumor diameter, median (cm, IQR)    0.50 (0.50 – 1.00)
Abbreviations: PUNLMP, papillary urothelial neoplasm of low malignant potential; BMI, body mass index; IQR, interquartile range
eases other than an urothelial malignancy. Univariate 
and multivariate Cox regression analyses were conduct-
ed to identify independent predictive factors for RFS of 
patients with PUNLMP (Table 2). On univariate and 
multivariate Cox regression analyses, previous history 
of urothelial neoplasm [95% confidence interval (CI) = 
0.057-0.604, HR = 0.185, P = .005] and multiplicity of 
tumors (95% CI = 0.064-0.584, HR = 0.193, P = .004) 
were identified as independent predictors for RFS of 
patients with PUNLMP. 
The RFS of groups who were categorized by previous 
history of urothelial neoplasm and multiplicity were 
calculated using the Kaplan-Meier method (Figure 1). 
The differences in RFS between groups were statisti-
cally significant (p < 0.001) as determined by the log 
rank test. 
DISCUSSION
PUNLMP has the histopathologic feature which re-
quires clinical follow-up even though it has limited 
biologic aggressiveness, and it may seem evident that 
it is generally regarded as malignancy because of the 
character that the recurrence and the progression might 
develop in PUNLMP.(16) However, it has been not cate-
gorized as malignancy. Reducing the psychological and 
financial hardship of patients who were diagnosed as 
cancer is one of the reasons that clinicians and pathol-
ogists do not regard PUNLP as carcinoma.(16) For the 
reason, clinicians should recommend regular follow-up 
for patients who have PUNLMP because of its clinical-
ly ambiguous characteristics. Traditionally, most clini-
cians have had difficulty in planning follow-up because 
the obvious prognosis of PUNLMP has not yet been 
identified. Several studies for identifying the prognosis 
and histopathologic predictive factors for recurrence or 
progression of PUNLMP have been conducted to im-
prove this situation.
Montironi et al. reported that chromatin organizational 
state is a predictive factor for the recurrence of PUN-
LMP,(10,11) and Mazzucchelli et al. reported that glob-
al acetylation and methylation changes predict the 
recurrence of PUNLMP.(12) It has also been reported 
that subtle architectural disorder detected by quantita-
tive analysis in DAXX (death domain-associated pro-
tein)-immunostained tissue sections in recurrent cases 
of PUNLMP may play a role in recurrence of this dis-
order.(13) Pich et al. reported that proliferative activity 
is the most significant predictor of recurrence in nonin-
Table 2. Predictors for recurrence free survival of PUNLMP 
Variables     HR 95%CI  P
    Univariate analysis
Age at being diagnosed with PUNLMP   0.998 0.940-1.059  0.948
Gender relative to male
 Female      0.409 0.069-2.435  0.326
BMI      1.609 1.060-2.442  0.025
Smoking history relative to absence
 Presence     0.932 0.037-23.247  0.966
Gross hematuria relative to absence
 Presence     0.886 0.225-3.486  0.862
Previous history of urothelial neoplasm relative to absence
 Presence     0.050 0.009-0.294  0.001
Cytologic result relative to ≤atypia, favor benign 
 ≥atypia, favor neoplastic    1.726 0.224 – 13.293 0.600
Multifocality relative to absence 
presence      0.075 0.016-0.361  0.001 
Tumor size     1.200 0.440-3.269  0.722
Multivariate analysis
BMI      1.110 0.903-1.365  0.323
Previous history of urothelial neoplasm relative to absence
Presence     0.185 0.057-0.604  0.005
Multifocality relative to absence
Presence     0.193 0.064-0.584  0.004 
Abbreviations: PUNLMP, papillary urothelial neoplasm of low malignant potential; HR, hazard ratio; CI, confidence interval; BMI, 
body mass index
Figure 1. a) Kaplan-Meier curve for recurrence (%) in group with 
previous history of urothelial neoplasm and group without previ-
ous history of urothelial neoplasm.
b) Kaplan-Meier curve for recurrence (%) in group with tumor 
multiplicity and group without previous history of urothelial ne-
oplasm.
Low malignant potential papillary urothelial neoplasm-Kim et al.
Urological Oncology  560
Vol 16 No 06  November-December2019   561
vasive PUNLMP and grade 1 papillary carcinomas of 
the bladder.(14) However, this study has the limitation 
that it combines patients with both noninvasive PUN-
LMP and grade 1 papillary carcinoma. Although these 
studies identified histopathologic predictive factors for 
recurrence of PUNLMP, the factors are not easily as-
sessed and applied to predictions of recurrence in the 
most clinical fields. 
Clinical data for identifying the prognosis and the prog-
nostic factor of PUNLMP have also been reported. Fujii 
et al. studied the long-term outcome of bladder PUN-
LMP(8) and reported that the 2-, 5-, and 10-year recur-
rence free rates were 66%, 51%, and 36%, respective-
ly. Maxwell et al. also reported results identified from 
long-term follow-up periods.(5) Although these clinical 
studies have the strength of long-term follow-up peri-
ods, they did not suggest any predictive factor for the 
recurrence of PUNLMP. Several authors reported that 
tumor multiplicity, tumor size, and prior recurrence rate 
are significant prognostic factors for prediction of re-
currence in non-muscle-invasive urothelial neoplasm 
that contain PUNLMP.(7,9) However, again these studies 
have the limitation that they did not include cases of 
PUNLMP exclusively. It has also been reported that the 
size of the initial tumor in patients with recurrences was 
significantly higher compared with those from patients 
with no recurrence, but this factor was not confirmed in 
multivariate analysis.(6) 
Recently, Zhang et al. identified age, tumor multiplici-
ty, and mitosis as significant prognostic factors for the 
recurrence of PUNLMP through multivariate analysis.
(4) Even though this report has a relatively small scale, it 
is important because the significant prognostic factors 
suggested in this study can be easily applied in clinical 
fields. 
Tumor multiplicity has been known as one of the prog-
nostic factors for RFS of superficial urothelial carci-
noma that has developed in bladder.(17) Patients with 
multiple tumors may have had increased risk because 
the probability of incomplete resection and microscop-
ic tumor dissemination increase with the number of 
tumor.(18) The current study also indicates that tumor 
multiplicity is a prognostic predictor for recurrence of 
PUNLMP, like the result reported by Zhang et al. The 
fact that these two studies show tumor multiplicity as 
a predictor of recurrence of PUNLMP indicates that 
PUNLMP should not be clinically regarded as a purely 
benign neoplasm.
The prior recurrence rate has also been known as one of 
the predictive factors for the recurrence of stage Ta T1 
bladder cancer.(17) Similarly, the current study results 
indicate that a previous history of urothelial neoplasm 
is one of the significant prognostic factors in PUNLMP. 
This similarity of results suggests PUNLMP is similar 
to a malignancy.
Although the proportion of PUNLMP cases with a pre-
vious history of urothelial neoplasm in most published 
studies has not been mentioned, PUNLMP cases with 
a previous history of urothelial neoplasm are not rare 
clinically. The study that was reported by Lee et al. 
showed that 29 of 63 patients with PUNLMP had a pre-
vious history of urothelial neoplasm.(6) A strength of the 
current study, in contrast with previous reported stud-
ies, is that the enrolled patients included patients with 
a previous history of urothelial neoplasm. These results 
suggest that more careful and closer follow-up should 
be recommended in patients with PULNMP who have a 
previous history of urothelial neoplasm. The results of 
the current study also show that tumor multiplicity and 
the previous history of urothelial neoplasm, which are 
prognostic factors of noninvasive urothelial carcinoma, 
can be applied as prognostic factors for the recurrence 
of PUNLMP. 
The results reported in the current study need to be con-
firmed and validated by analyzing data from a larger 
prospective study because they may have been affected 
by the retrospective nature of the study and the small 
number of enrolled patients.
CONCLUSIONS
In the current study, we found that tumor multiplicity 
and previous history of urothelial neoplasm are inde-
pendent prognostic factors for the prediction of re-
currence of PUNLMP. Clinicians should recommend 
careful and close follow-up of PUNLMP patients who 
have tumor multiplicity or previous history of urothelial 
neoplasm. 
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